JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Tel: +1-832-696-8203
Email: [email protected]
Worldwide Distributors
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Betamethasone is a synthetic corticosteroid and agonist of glucocorticoid receptor [1].
Betamethasone has shown the inflammatory response by the betamethasone-receptor complex modulated the activity of certain genes, altering the production and activity of proteins. These proteins include phospholipase A2, cyclooxygenase-2 and NO-synthase. Betamethasone has been reported to inhibit the expression of these enzymes results in reduced production of such inflammatory mediators as prostaglandins, leukotrienes and nitric oxide. In addition betamethasone has also revealed to inhibit keratinocyte proliferation [1].
References:[1] Pharmacology Review(s)-FDA.
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021852s000_PharmR.pdf
Cell lines
Human astrocytoma
Preparation method
The solubility of this compound in DMSO is >19.6 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.
Reacting condition
10 μg/ml
Applications
Bexamethasone (1.3-50 μg/ml) decreased cloning efficiency and colony size in cultured human astrocytoma. In MRC5 human diploid fibroblasts, betamethasone (8 μg/ml) increased cloning efficiency by two-fold. Betamethasone (2-16 μg/ml) did not affect colony size.
Animal models
Pregnant rabbits, Pregnant ewes
Dosage form
0.5 mg/kg
Application
Pregnant rabbits were injected with either 0.8 mg of betamethasone on days 24 and 25 of gestation and delivered by cesarean section on day 26. Bexamethasone significantly reduced the weight of fetuses and fetal brain, lungs, liver, and placenta. In pregnant ewes, BET (0.5 mg/kg) decreased fetal (121–146 dG) and placental (121 dG) weights. Maternal plasma oPL levels in controls increased across gestation; fetal plasma oPL levels decreased. BNCs were reduced by 24% to 47% after BET. Placental oPL protein levels, maternal and fetal plasma oPL levels were also reduced after BET injections, but recovered to values that were not different to controls near term. BET (0.5 mg/kg) disrupted the normal distribution of BNCs within the placentome.
Other notes
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.
References:
[1]. Guner M, Freshney R I, Morgan D, et al. Effects of dexamethasone and betamethasone on in vitro cultures from human astrocytoma[J]. British journal of cancer, 1977, 35(4): 439.
[2]. Barrada M I, Blomquist C H, Kotts C. The effects of betamethasone on fetal development in the rabbit[J]. American journal of obstetrics and gynecology, 1980, 136(2): 234-238.
[3]. Braun T, Li S, Moss T J M, et al. Maternal betamethasone administration reduces binucleate cell number and placental lactogen in sheep[J]. Journal of Endocrinology, 2007, 194(2): 337-347.